Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium mitochondrial cytochrome b (CytB) is a key, mitochondrially encoded subunit of the ubiquinol-cytochrome c reductase complex (Complex III or cytochrome bc1 complex) in the mitochondrial electron transport chain (mETC) of malaria-causing Plasmodium parasites. It plays an essential role in parasite survival across multiple life cycle stages by facilitating electron transfer from ubiquinol to cytochrome c, which helps generate the proton gradient across the inner mitochondrial membrane necessary for ATP synthesis. In asexual blood-stage parasites, this electron transport is also critically coupled to the recycling of ubiquinone, which is required by dihydroorotate dehydrogenase (DHODH) for de novo pyrimidine biosynthesis. Because Plasmodium cannot salvage preformed pyrimidines, disruption of cytochrome b function halts nucleic acid replication and leads to parasite death.
Cytochrome b is a highly validated drug target, most notably inhibited by the clinically approved antimalarial drug atovaquone (often co-formulated with proguanil as Malarone). Atovaquone acts as a ubiquinol mimic that binds to the quinol oxidation (Qo) site of cytochrome b, collapsing the mitochondrial membrane potential. However, the therapeutic utility of atovaquone is threatened by the rapid de novo emergence of single point mutations in the cytochrome b gene, particularly at codon Y268, which confer high-level resistance. To overcome this challenge, novel preclinical inhibitors such as endochin-like quinolones (e.g., ELQ-300) have been developed to target the distinct quinone reduction (Qi) site of the complex, offering potential dual-site inhibition strategies to delay or prevent resistance.
Inhibition of the mitochondrial electron transport chain, depolarization of mitochondrial membrane potential, and inhibition of pyrimidine biosynthesis.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium mitochondrial cytochrome b (CytB).